A growing number of drug-resistant bacteria has researchers calling for the development of novel antibiotics to treat them.
Canada lags behind other developed countries in access to newer antimicrobials. Here’s why that matters, and what can be done about it.
An interdisciplinary team of McMaster researchers is recommending Canadian public health officials change how novel antibiotics are approved, procured and accessed in Canada in order to fight the growing threat of antimicrobial resistance (AMR).
McMaster logo
McMaster logo
